Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 672

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 672
---
 IFRS 9 and IFRS 7 — Amendments to the Classification and Measurement of Financial Instruments. The amendments are effective for reporting periods beginning on or after 1 January 2026. The Group is currently analyzing the potential impact of these new standards on our financial statements. 2.3Foreign currency Foreign currency transactions are translated into the functional currency of the Company using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year -endexchange rates of monetary assets and liabilities nominated in foreign currencies are recognized in the profit or loss for the year. Foreign exchange gains and losses are presented in the statement of operations within other financial income, as appropriate, unless they have been capitalized. 2.4Revenue recognition The Group operates through two operating segments, Rewell and Heritas Diagnostics. The Group recognizes revenue when control of the services are fully delivered to customers when performance obligations are met. This is recognized at an amount that reflects the consideration to which the Group expects to receive in exchange for transferring these services to customers (the “Transaction Price”). Heritas Diagnostics Segment Revenues from the Group’s Heritas Diagnostics segment are typically generated from genetic sequencing and diagnostics services covering the fields of oncology, prenatal care, rare diseases and clinical gut health, and provides other genetic sequencing services. The Group has entered into a commercial partnership with Cibic — Centro de Diagnóstico Medico de Alta Complejidad S.A. (“CIBIC”), a shareholder of OminigenicsAI Corp., for the purpose of providing these clinical genetic tests. Under this partnership agreement, CIBIC exclusively handles the commercialization of all Heritas Diagnostics clinical genetic tests in Argentina. (See Note 2.10 — Trade and other receivables, net) The Group identified a single performance obligation, namely, the delivery of the analysis results to CIBIC. The Group enables CIBIC to include these tests in its service portfolio, with CIBIC responsible to market these tests directly to patients and stakeholders in the healthcare industry, including physicians and healthcare institutions. CIBIC collects patient samples from its medical centers and delivers them to the Group’s laboratory for processing. Once the samples are received and processed, the Group generates reports with the results, which CIBIC then delivers to the patients and physicians. The Group establishes a price for each test, which CIBIC pays per test sold. CIBIC independently determines the retail price at which it